You are here

Coronary Intervention & Surgery


Hospitals ranked in the top 50 for cardiology and heart surgery by U.S. News and World Report appear no better at performing PCI than unranked hospitals, according to an analysis of more than 500,000 procedures performed at 654 hospitals.

PCI of chronic total occlusions (CTOs) can be safely performed by expert operators and provides significant benefit to patients with reduced left ventricular ejection fraction (LVEF) or diabetes, according to a series of studies published Nov. 13 in JACC: Cardiovascular Interventions.

Scaffold discontinuity, malapposition and neoatherosclerosis were found to be the leading mechanisms behind very late scaffold thrombosis (VLScT) in cardiac patients implanted with bioresorbable devices, investigators from the INVEST registry have reported.

Recent studies have shown robotic PCI to be a feasible way to treat coronary artery disease. But at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference Oct. 30, Ryan D. Madder, MD, took the conversation a step further: Will it eventually be possible to perform “tele-stenting” over long distances?

Research presented Nov. 2 at the Transcatheter Cardiovascular Therapeutics scientific symposium in Denver demonstrates patients with stable coronary artery disease (CAD) and abnormal fractional flow reserve (FFR) derive better clinical outcomes with PCI at similar cost to medical therapy alone.


Recent Headlines

Researchers pinpoint how cells get damaged during cardiac surgeries

New findings on how cardiac muscle cells are damaged during surgery could point to emerging methods that will allow hearts to recover more quickly.

Transparency helps reduce inappropriate PCI rates

In early 2012, hospitals in New York received reports from the state on their inappropriate PCI rates. The state later published the rates in a medical journal and recommended that payers deny reimbursement for inappropriate PCIs in Medicaid patients.

Researchers will use stem cell therapy to grow heart muscle in new study

The U.S. Food and Drug Administration (FDA) has approved a new study that will test the efficacy of a stem cell technique used on children suffering from congenital heart disease.

PCI operators have significant variability in risk-standardized mortality rates

A registry analysis found there was significant variability in risk-standardized mortality rates among PCI operators who met minimum volume standards. The rates were not consistent on a yearly basis.

Merit Medical recalls device used to guide catheters, grafts into veins, arteries

Merit Medical Systems recalled its Merit 7F Prelude short sheath introducer, which is used to guide the placement of catheters, grafts and other medical devices into the veins and arteries. It is also used during temporary hemodialysis.

ACC.17: LAAO at the time of cardiac surgery may reduce thromboembolism, mortality

Older adults with atrial fibrillation who underwent left atrial appendage occlusion (LAAO) at the time of cardiac surgery had an approximately 40 percent reduction in thromboembolism and a 15 percent reduction in all-cause mortality, according to a database analysis.

ACC.17: Levosimendan improves outcomes for heart surgery patients

Levosimendan, a drug used to prevent heart failure during heart surgery, was shown to not reduce adverse outcomes in patients at a high risk for low cardiac output syndrome in a new study debuted at the American College of Cardiology’s 66th Annual Scientific Session.

ACC.17: ABSORB III trial shows stent associated with increased risk of adverse outcomes

New results on Abbott Vascular’s Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) were revealed at this year’s American College of Cardiology (ACC)’s Scientific Session, providing disappointing results for the stent that are consistent with a trend set by previous studies.

ACC.17: Cerebral embolic protection devices may not improve freedom from stroke, infarction

A randomized study found that using two FDA-approved cerebral embolic protection devices in patients undergoing surgical aortic valve replacement (SAVR) was not associated with an improvement in freedom from clinical or radiographic infarction or clinical stroke.

ACC.17: Revascularization strategies guided by FFR, iFR have similar adverse cardiac event rates

At 12 months, patients with stable angina or acute coronary syndrome had similar rates of major adverse cardiac events whether they underwent revascularization guided by instantaneous wave-free ratio (iFR) or fractional flow reserve (FFR), according to a randomized, registry-based trial.